Tirzepatide: A Research Sourcing & Verification Guide

Tirzepatide is the most-referenced dual agonist in the incretin-peptide research class — the compound most studies reach for when the question is what co-engaging the two incretin receptors contributes over single-receptor agonism. If you are sourcing it as reference material for laboratory work, two things matter before price: knowing exactly what the molecule is on paper, and being able to prove the vial in front of you contains it at documented purity. This guide covers both, then walks through how sourcing a Tirzepatide reference sample actually works.

Everything below is framed for laboratory and research use only. Nothing here is medical guidance, dosing information, or a claim about outcomes in humans. It is a map of mechanism and provenance, so a researcher can identify the molecule and verify the material.

What Tirzepatide is, on paper

Tirzepatide is a 39-amino-acid synthetic peptide, fatty-acid modified to extend its half-life, studied as a dual agonist of the two incretin receptors. Its identity is fixed by a single line every serious listing should carry:

The CAS number is the anchor. It ties the name on the label to a specific molecular entity, which is why a listing that shows a CAS identifier alongside a lot-level Certificate of Analysis lets you confirm both what the molecule is and whether this batch matches it.

The dual-incretin mechanism, briefly

"Dual agonist" counts the metabolic receptors Tirzepatide is designed to engage — and specifically, it engages the two incretin receptors rather than pairing an incretin with the glucagon axis:

• GLP-1 receptor. The foundational incretin target and the most heavily characterized pathway in the class, studied around glucose-dependent insulin signaling and energy-balance regulation in preclinical models.
• GIP receptor. The second incretin receptor. Adding GIP engagement alongside GLP-1 is the exact variable that distinguishes Tirzepatide from single GLP-1 agonists such as Semaglutide.

This is the "both incretins" pairing. It contrasts with the GLP-1/glucagon dual agonists (Survodutide, Mazdutide) and with Retatrutide, the triple agonist that adds the glucagon receptor on top of Tirzepatide's two. For the full class map, see the GLP-1 research compounds comparison.

Verifying a Tirzepatide sample: reading the COA

A receptor profile on paper only matters if the vial actually contains the labeled compound. For a research chemical, the Certificate of Analysis is the whole proof, and a real one for Tirzepatide names five things:

1. The analyte. It should say Tirzepatide, matching the vial and the CAS number above. A generic or mismatched analyte is the first tell.
2. The lab. An independent third-party lab (for example Freedom Diagnostics or Janoshik), not the seller. A vendor grading its own product is a claim, not a certificate.
3. The lot. A batch number tying this certificate to this production run. If the lot on the vial does not appear on a certificate, the certificate is not for what you are holding.
4. The method and result. HPLC for purity with an actual number, and mass spec for identity. "99%+" floating on a logo is marketing; an assay figure on a dated report is data.
5. Independent verification. Where a Janoshik report is provided, its verify link resolves on janoshik.com — the lab's own domain, not the vendor's. If a "verify" link only ever points back to the seller's server, that is not third-party verification.

New to reading these? Start with how to read a peptide COA, then check a live example against the BBA COA library.

How research buyers source Tirzepatide

Once identity and purity are settled, sourcing comes down to three practical variables:

• Origin and lead time. US in-stock material ships on a fast domestic line with a stated dispatch window; overseas catalog stock carries a longer, labeled window. Neither is disqualifying, but a supplier should tell you plainly which one you are buying. See US-stock vs overseas research peptides for the full trade-off.
• Single vial vs. kit, and minimums. A forced 10-vial minimum is often a way to move dead stock. For a comparison series or a first-time identity check, the ability to buy a single vial matters.
• Suspiciously low pricing. Real HPLC/MS testing costs money per batch. Dramatically below-market pricing usually means something got cut. A transparent payment-fee difference is a separate thing from a quality cut — know which one you are looking at.

How BBA supplies Tirzepatide (disclosed: this is our store)

Full disclosure — bbapeptides.com is our storefront, so treat this as us showing our work against the checklist above, not neutral testimony:

• US in-stock, supplied as lyophilized powder in research vials, as single vials and kits — with no order minimum, so you can buy one.
• CAS 2023788-19-2 on the listing, so the molecular identity is stated, not implied.
• A real, batch-linked third-party COA for the lot you receive, from independent labs, with a Janoshik verify link that resolves on the lab's own site. Don't take our word for it — open a certificate and check it yourself.

Availability and current sizes rotate as new lots land, so the live Tirzepatide listing is the place to confirm in-stock status and open the current lot's certificate. Checkout is simple — pay with crypto (Bitcoin, USDC, or Ethereum at the listed total) or PayPal, which includes a 10% checkout premium.

A note on how it is supplied

Tirzepatide is supplied as lyophilized powder in a research vial, reconstituted per the researcher's own laboratory protocol, and is intended for laboratory and research use only — not for human or animal consumption. It is characterized by a lot-level Certificate of Analysis for identity and purity. Nothing in this article should be read as guidance for use in humans.